Gastric Adenocarcinoma

P3, N=324, Recruiting, Federation Francophone de Cancerologie Digestive | Not yet recruiting --> Recruiting

Nonetheless, primary and acquired resistance driven by HER2 heterogeneity, immune evasion, and dynamic molecular evolution remain major challenges. Next-generation HER2-targeted therapies, including bispecific antibodies, novel antibody - drug conjugates, and dual HER2 antibodies will be crucial to further improve outcomes in this population.

This case highlights the diagnostic challenge posed by TTF-1-positive gastric tumors, which may be mistaken for metastatic lesions from lung cancer. As TTF-1 expression is not entirely specific to tissues of lung or thyroid origin, diagnosis should be based on a comprehensive evaluation of morphological and immunohistochemical findings, together with clinical information, including treatment response and disease course.

Survival in gastric PM is fundamentally driven by HER2 status and the extent of PM. Surgical detection identifies a subgroup with limited, occult disease who achieve superior outcomes compared to those with radiologically overt metastases. Furthermore, the magnitude of biomarker elevation, rather than mere positivity, serves as a critical stratifier. These findings support a paradigm shift towards burden-based risk stratification to guide treatment intensity and clinical trial eligibility.

P3, N=450, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting

P=N/A, N=160, Recruiting, Samsung Medical Center | Not yet recruiting --> Recruiting | Initiation date: Sep 2025 --> Jan 2026

P2, N=60, Not yet recruiting, Ruijin Hospital

We successfully established a spontaneous GAC model and its corresponding cell line in C57BL/6J mice, enabling a comprehensive investigation of tumor progression, metastasis, therapeutic response, and resistance mechanisms in vivo. This model represents a valuable platform for advancing precision medicine in gastric cancer.

P1, N=42, Terminated, Prelude Therapeutics | Trial completion date: Apr 2027 --> Jan 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2026 --> Jan 2026; Sponsor decision

The tumor demonstrated significant shrinkage following PRaG treatment and ultimately achieved pathologic complete response (pCR), with no serious adverse events aside from mild abdominal pain (NRS score 2). This case suggests that PRaG therapy may represent a promising therapeutic approach for patients with metastatic HAS.

Its high expression integrates tumor-intrinsic programs (cell cycle, EMT, hypoxia) with tumor-extrinsic immune activation, predicts differential drug sensitivities, and outperforms established biomarkers in forecasting response to immune-checkpoint blockade-particularly in MSI-high disease. These findings nominate IFI30 as a promising diagnostic marker and therapeutic target.

Clinicopathological characteristics and baseline peripheral lymphocyte subsets were significantly associated with efficacy of first-line chemotherapy combined with ICIs in pMMR HER2-negative advanced G/GEJC, highlighting the potential utility of integrating these accessible parameters for efficacy prediction.